Clinical significance of MDM2 as a tumor biomarker

R730.4; MDM2 (the product of murine double minute 2 gene) is one of the most important negative regulators of p53, which can binds to p53 and initiates ubiquitin-mediated degradation. Besides, MDM2 also controls the activity of several cell-cycle regulators, e.g. pRB, p21, E2F1, independently of p53...

Full description

Saved in:
Bibliographic Details
Published in中德临床肿瘤学杂志（英文版） Vol. 11; no. 6; pp. 356 - 360
Main Authors Hong Chen, Li Xie, Baomi Liu
Format Journal Article
LanguageEnglish
Published Department of Oncology, People's Hospital of Yixing City, Yixing 214200, China%Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing 210008, China 2012
Subjects
MDM2
predictive biomarker
oncogene
p53
Online AccessGet full text

Cover

More Information
Summary:R730.4; MDM2 (the product of murine double minute 2 gene) is one of the most important negative regulators of p53, which can binds to p53 and initiates ubiquitin-mediated degradation. Besides, MDM2 also controls the activity of several cell-cycle regulators, e.g. pRB, p21, E2F1, independently of p53. The important role of MDM2 in cell-cycle regulation indicates it to be a point of interest in cancer research. In recent years, studies revealed that MDM2 participated in the genesis and development of human tumors. The expression levels and activity of MDM2 was associated with the invasion, metastasis, prognosis and more practical, chemosensitivity. MDM2 is becoming a novel biomarker in cancer prognosis and chemosensitivity prediction.
ISSN:1610-1979
DOI:10.1007/sl0330-012-0986-9